PAST SPEAKERS
Judy Chou
President and CEO of AltruBio
Uwe Gottschalk
Operating Partner at Keensight Capital
Nuno Fontes
SVP, Head of Global CMC at WuXi Biologics
For the patients, we must do better.
18th Annual Bio Innovation Leaders Summit 2026
11th & 12th February 2026
London (exact location TBC)
Co-Located 4th Annual Meat Evolution Leaders Summit #MEVO
For the patients, we must do better.
BILS 2026. The 18th Annual Bio Innovation Leaders Summit 2026
This exclusive gathering will host up to 200 qualified leaders, including business executives, VP's and C-suite executives - in person only. It will provide a unique opportunity to engage in high-level discussions on how biomanufacturing is not only driving innovation and business growth but also enhancing patient outcomes and shaping a more sustainable healthcare future.
-
End-to-end insights across biologics, cell and gene therapy and RNA manufacturing
-
Real-world case studies on tech transfer, scale-up, single-use systems and digital automation
-
High-impact leadership sessions on AI integration, outsourcing strategies and regulatory alignment
CURRENT SPEAKERS
AGENDA SCHEDULE
Who Attends
-
Chief Manufacturing Officer (CMfO)
-
VP/Head of Biomanufacturing or Technical Operations
-
VP/Head of CMC (Chemistry, Manufacturing & Controls)
-
VP/Head of Process Development or MSAT
-
VP/Head of Digital Manufacturing, AI, or Automation
-
VP/Head of External Manufacturing or IND Strategy
Why Attend BILS 2026 – Bio Innovation Leaders Summit?
BILS 2026 is the definitive, invite-only gathering for senior leaders driving the future of biomanufacturing, CMC, IND strategy, and bioprocess innovation. Designed exclusively for C-suite, VP's and decision-makers
This strategic alignment facilitates a deeper understanding of the interconnectedness of health and food industries, paving the way for integrated solutions that address global challenges.
In summary, the co-location of BILS 2026 and MEVO 2026 creates a dynamic platform for interdisciplinary collaboration, driving innovation and sustainable growth at the intersection of biomanufacturing and cultivated protein industries.
Joshi Venugopal
GM & Head of Europe
Novartis Gene Therapies & Rare Diseases
Dorothee Ambrosius
Former Head of CMC Strategy Biologicals
Boehringer Ingelheim
Warner Biddle
Former Global Head of Commercial
Kite, a Gilead Company
Gwendolyn Binder
President of Science & Technology
Cabaletta Bio
Pierre Caloz
COO
uniQure
Paolo Martini
Former CSO
Moderna
IN PERSON ONLY
Unmatched peer exchange with up to 200 qualified executives tackling shared challenges in speed, quality and sustainability
SUMMIT
INSIGHTS
Our Mission
Our purpose is to create a gathering that empowers and inspires critical decision-making; sparking new opportunities to amplify their impact within the biologics and cell and gene therapy value chain.
We encourage collaboration and innovation, which is why this summit ensures that each participant contributes significantly to advancing the field. It serves as a platform for sharing insights, fostering partnerships and driving forward the next wave of breakthroughs in biologics.
For the patients, we must do better.
Investors and large biopharma companies need to satisfy environmental compliance. We will keynote the progression toward more sustainable bioprocesses, manufacturing and supply methods, amalgamating toward building a sustainable and digitised ecosystem - an emerging frontier of digitisation and industry 4.0.
Closing session by Merck.
Attendee Profile
C-Suite - Directors - Executives
Bioprocess - Manufacturing - IT-Data Integration - Commercial and Business Development - Scientists - Supply Chain - Production - PAT
Focus Area
CGT
Antibody Drugs
Vaccine
Small molecule, conjugates and peptides
Technology or Service Companies
CRO
CDMO
Biologic workflow solutions
Advance Bioprocessing
End to end workflow solutions
Digitising - AI - Data
Automation - Robotics
Filtration - Single use - Bioreactors
Event highlights
Pre Event Innovation Tour - Private Innovation Tour - CXO
Please click to Tour 2024
Evening of day one -Private Networking Dinner
Journey of a CXO
Exclusive closed-door talks from some of the most prominent leaders in the industry who will be talking about their journey, lessons learnt and vision for the future.
Attendance Guide
30% Asian Biopharma
25% International Biopharma
20% CMOs - CDMOS's
15% Academic & Research Institutes
10% Technology & Service Providers
Curated Meetings
Packages have sold out
Guaranteed pre-qualified strategy meetings
Prior contact
Mutual benefit
Conducted by our specialists
Geography
25% Korea & Japan
20% Singapore
20% Indonesia, Thailand, Philippines, Malaysia, India & Australia
15% China, Hong Kong & Taiwan
15% USA
5% UAE
PREVIOUS SPEAKERS
For the patients, we must do better
ADVISORY
Join BILS 2026 to shape the next decade of biologics manufacturing
